Benning Louise, Töllner Maximilian, Hidmark Asa, Schaier Matthias, Nusshag Christian, Kälble Florian, Reichel Paula, Buylaert Mirabel, Grenz Julia, Ponath Gerald, Klein Katrin, Zeier Martin, Süsal Caner, Schnitzler Paul, Morath Christian, Speer Claudius
Department of Nephrology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Institute of Immunology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Vaccines (Basel). 2021 Aug 4;9(8):857. doi: 10.3390/vaccines9080857.
Despite limited data on safety and immunogenicity, heterologous prime-boost vaccination is currently recommended for individuals with ChAdOx1 nCoV-19 prime immunization in certain age groups. In this prospective, single-center study we included 166 health care workers from Heidelberg University Hospital who received either heterologous ChAdOx1 nCoV-19/BNT162b2, homologous BNT162b2 or homologous ChAdOx1 nCoV-19 vaccination between December 2020 and May 2021. We measured anti-S1 IgG, SARS-CoV-2 specific neutralizing antibodies, and antibodies against different SARS-CoV-2 fragments 0-3 days before and 19-21 days after boost vaccination. Before boost, 55/70 (79%) ChAdOx1 nCoV-19-primed compared with 44/45 (98%) BNT162b2-primed individuals showed positive anti-S1 IgG with a median (IQR) anti-S1 IgG index of 1.95 (1.05-2.99) compared to 9.38 (6.26-17.12). SARS-CoV-2 neutralizing antibodies exceeded the threshold in 24/70 (34%) of ChAdOx1 nCoV-19-primed and 43/45 (96%) of BNT162b2-primed individuals. After boosting dose, median (IQR) anti-S1 IgG index in heterologous ChAdOx1 nCoV-19/BNT162b2 vaccinees was 116.2 (61.84-170), compared to 13.09 (7.03-29.02) in homologous ChAdOx1 nCoV-19 and 145.5 (100-291.1) in homologous BNT162b2 vaccinees. All boosted vaccinees exceeded the threshold for neutralization, irrespective of their vaccination scheme. Vaccination was well-tolerated overall. We show that heterologous ChAdOx1 nCoV-19/BNT162b2 vaccination is safe and induces a strong and broad humoral response in healthy individuals.
尽管关于安全性和免疫原性的数据有限，但目前建议在特定年龄组中，对接受过ChAdOx1 nCoV-19初免的个体进行异源序贯接种。在这项前瞻性单中心研究中，我们纳入了海德堡大学医院的166名医护人员，他们在2020年12月至2021年5月期间接受了异源ChAdOx1 nCoV-19/BNT162b2、同源BNT162b2或同源ChAdOx1 nCoV-19疫苗接种。我们在加强接种前0至3天和加强接种后19至21天测量了抗S1 IgG、SARS-CoV-2特异性中和抗体以及针对不同SARS-CoV-2片段的抗体。加强接种前，55/70（79%）接受ChAdOx1 nCoV-19初免的个体与44/45（98%）接受BNT162b2初免的个体相比，抗S1 IgG呈阳性，抗S1 IgG指数中位数（IQR）分别为1.95（1.05 - 2.99）和9.38（6.26 - 17.12）。24/70（34%）接受ChAdOx1 nCoV-19初免的个体和43/45（96%）接受BNT162b2初免的个体的SARS-CoV-2中和抗体超过阈值。加强接种后，异源ChAdOx1 nCoV-19/BNT162b2疫苗接种者的抗S1 IgG指数中位数（IQR）为116.2（61.84 - 170），同源ChAdOx1 nCoV-19疫苗接种者为13.09（7.03 - 29.02），同源BNT162b2疫苗接种者为145.5（100 - 291.1）。所有加强接种的疫苗接种者均超过了中和阈值，无论其接种方案如何。总体而言，疫苗接种耐受性良好。我们表明，异源ChAdOx1 nCoV-19/BNT162b2疫苗接种是安全的，并能在健康个体中诱导强烈且广泛的体液免疫反应。
